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ABSTRACT (200 words) 
Background and aims: Non invasive approaches are useful to differentiate simple steatosis from non-
alcoholic steatohepatitis (NASH) in obese and morbidly obese patients. The aim of this study was to 
develop a new scoring system to diagnose definitive NASH.  
Methods: Preoperative clinical and biological data including serum caspase 3-generated cytokeratin-18 
fragments (CK18) and peroperative liver biopsies were obtained from 464 morbidly obese patients 
who had undergone bariatric surgery. The cohort was divided into two groups: training group (n=310) 
and validation group (n=154). Definitive NASH was defined according to Kleiner’s classification with 
a NAFLD Activity Score (NAS) ≥5.  
Results: Alanine aminotransferase (ALT), CK18 fragments and the presence of metabolic syndrome 
(MS) were independent predictors for discriminating patients with NAS ≥5 in the training group. These 
three parameters were used to carry out a scoring system for the prediction of NAS ≥5. Whereas serum 
CK18 fragment alone had an Area under the Receiver Operating Characteristic (AUROC) curve = 0.74, 
AUROC curves of the scoring system were 0.88 and 0.83 in the training and in the validation group 
respectively.  
Conclusion: A simple and non invasive composite model including MS, ALT and CK18 fragments 
was able to accurately predict NAS ≥5 in morbidly obese subjects. 
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3 
MAIN TEXT 
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of pathological liver abnormalities ranging 
from pure steatosis to non-alcoholic steatohepatitis (NASH), and finally to severe fibrosis and 
cirrhosis.1 Classically, pure steatosis has a relatively good prognosis whereas steatohepatitis is 
associated with progression of liver fibrosis.2, 3 Thus, differentiation of these two states is important. 
NAFLD is common in the context of morbid obesity and NASH can be present in 20−40% of these 
patients.4, 5  
The mechanisms of NAFLD development are complex and poorly understood. Chronic low grade 
chronic inflammation, adipokines dysregulation and insulin resistance in the liver and visceral adipose 
tissue are the major contributing factors.6, 7 NAFLD has been considered as the hepatic manifestation 
of so-called “metabolic syndrome”(MS), a syndrome highly related to morbid obesity with its well 
defined components: increased waist circumference, high blood pressure, high blood triglycerides, low 
blood high-density lipoprotein (HDL) cholesterol, and high blood glucose level.5, 8-10 Hepatocyte 
apoptosis may also play an important role in the liver injury and disease progression in NAFLD.11 
Liver biopsy is still considered the gold standard to assess hepatic pathology in most chronic liver 
diseases, including NAFLD, but it is an invasive technique. Moreover, liver biopsy is associated with 
sampling and inter-observer variability, which might explain the differences in prevalence of NASH in 
morbidly obese patients reported in previous studies.4, 12, 13 In addition, the large number of patients 
with morbid obesity exposed to NAFLD renders systematic liver biopsy in all patients difficult. The 
availability of a non-invasive test would allow systematic diagnosis in this particularly predisposed 
subpopulation and would enable repeated assessment during the follow-up in a more feasible way than 
liver biopsy. Unfortunately, medical imaging techniques (ultrasound, computerized tomography and 
magnetic resonance imaging) fail to differentiate pure steatosis from NASH.14 Moreover, echography 
in severely or morbidly obese patients is frequently of poor quality.  
Several non-invasive scoring models using routine clinico-biological parameters have been proposed 
for the diagnosis of NASH, but most of them have not been thoroughly validated.15-19 
Recently, apoptotic caspase-3 generated cytokeratin 18 (CK18) fragments in the blood were reported 
to predict histological NASH in cohorts of obese patients or in patients with insulin resistance.20-23  
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4 
The aim of this study was to develop a scoring system to diagnose definitive NASH using clinical and 
biological data related to the metabolic syndrome and liver injury including caspase-3 generated CK18 
fragment, in a large cohort of European morbidly obese patients.  
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5 
Patients and Methods  
Study population 
 Four-hundred and sixty four consecutive morbidly obese patients, referred for bariatric surgery, were 
included between January 2003 and April 2009. A division of the initial cohort in 2 groups was carried 
out in order to be able to have a training and a validation patient cohort. The patients were arbitrarily 
divided into two groups: (i) a training patient cohort consisting of 310 patients (43 men, 267 women, 
mean age 40.0±10.7 years) enrolled from January 2003 to April 2007; and (ii) a validation patient 
cohort consisting of 154 patients enrolled from May 2007 to April 2009.  
The study protocol was performed according to French legislation regarding Ethic and Human 
Research and was approved by the local Ethics Committee (Huriet-Serusclat law, DGS 2003/0395). 
Written informed consent was obtained from all patients. All patients met the 1991 NIH 
Consensus Conference guidelines for gastrointestinal surgery for obesity.24 All patients were negative 
for hepatitis B and C viral markers, autoantibodies indicative of autoimmune hepatitis, and had 
negligible alcohol consumption (<20 g/day). Alcohol abuse was also excluded by interviewing the 
patients’ relatives. Patients with a history of inflammatory disease (including rheumatoid arthritis, 
systemic lupus erythematosus, and inflammatory bowel disease), current infections, recent history 
of cancer (<5 years), and severe pulmonary or cardiac disease were not enrolled in the study. All 
patients underwent a Roux-en-Y divided gastric bypass and a surgical liver biopsy was obtained 
during surgery. 
Preoperative assessment 
Preoperative assessment included:  history and physical examination; blood pressure determination; 
anthropometric investigations (weight, height, waist circumference); psychiatric and nutritional 
evaluation; blood samples were also obtained before surgery after overnight fasting for the 
determination of plasma levels of alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), γ glutamyl transferase (γGT), glucose, insulin, C-peptide, glycosylated hemoglobin, 
triglycerides, HDL cholesterol, low density lipoprotein (LDL) cholesterol, ferritin. ALT and AST 
levels were determined using the Roche® assay with pyridoxal phosphate on a Hitachi Modular® 
according to the International Federation of Clinical Chemistry and the Société Française de Biologie 
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6 
Clinique recommendations. Glycosylated hemoglobin was obtained with the Dual kit A1c Biorad® on 
a Variant 2 Biorad® (Biorad, USA). Blood levels of apoptotic caspase-3 generated CK18 fragment 
levels were measured using ELISA kit M30-Apoptosense® (Peviva, Bromma, Sweden) according to 
the manufacturer’s instructions. All patients also had a chest X ray, electrocardiogram, abdominal 
ultrasound and upper gastrointestinal endoscopy.   
Insulin resistance was assessed by homeostasis model assessment of insulin resistance (HOMA-IR). 
HOMA-IR is the product of fasting plasma insulin concentration (mIU/L) and glucose 
concentration (mmol/L) divided by 22.5.25 
MS was diagnosed according to the International Diabetes Federation (IDF) as follows: central 
obesity defined by a increased waist circumference (≥80 cm in women and ≥94 cm in men) and any 
two of the following criteria: (i) triglycerides ≥1.7 mmol/L or treatment for hypertriglyceridemia; (ii) 
HDL-cholesterol <1.29 mmol/L in women and <1.03 mmol/L in men; (iii) systolic blood pressure (BP) 
≥130 mmHg or diastolic BP ≥85 mmHg or treatment for hypertension; and (iv) fasting plasma glucose 
≥5.6 mmol/L or previously diagnosed type-2 diabetes. (8) All the morbid obese patients of this study 
had a rise in the waist circumference. Type-2 diabetes was defined by two measurements of elevated 
fasting plasma glucose ≥7 mmol/L. 
Pathological liver assessment 
Hepatic wedges were obtained during bariatric surgery. Surgical liver biopsies were reviewed by two 
liver pathologists (MC-SP and SP) without knowledge of the clinical or biological characteristics of 
the patients.  Routine haematoxylin-eosin-safran and sirius red staining were performed on all 
biopsies. All biopsies were graded according to the NAFLD Activity Score (NAS). This score 
classifies patients as simple steatosis (NAS≤2), borderline group (3≤NAS≤4) or definitive NASH 
(NAS≥5).26 Patients were analyzed as with or without NAS ≥5. 
Liver bridging fibrosis was assessed by sirius red staining and was classified into five stages as 
follows: absent, mild, moderate (incomplete septa), severe (with complete septa) and cirrhosis.  
Statistical analysis 
Statistical analysis was first performed on the training patient cohort (n=310) in three steps:  (i) 
univariate analysis of clinical and biochemical parameters was carried out for patients with NAS <5 and 
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7 
NAS ≥5. The most relevant parameters for classifying the patients were noted. Continuous data are 
described as means ± standard deviation (SD). Comparisons were done using the Chi2 test or Fischer’s 
exact tests for nominal data and by two-sample t tests for continuous data; (ii) multivariate analyses were 
performed using binary logistic regression with estimation of odds ratios (OR) and 95% confidence 
intervals (95%CI). The most statistically significant (with p<0.05) and clinically relevant variables in the 
univariate step were included in a multivariate model, and only variables with p<0.05 were retained for 
the final model; (iii) the final model was determined by logistic regression to predict NAS ≥5 and based 
on three parameters: CK18 fragment levels, ALT and MS. The diagnostic performance of this model 
was determined by constructing a receiver-operating characteristic (ROC) curve and calculating the area 
under ROC (AUROC) curve for predicting patients with NAS ≥5. From this curve, the best cut-off value 
was established for the model score; this value maximized the sum of the sensitivity and specificity to 
identify patient status. The diagnostic accuracy of the logarithmic transformation of the Nice Model 
(Prob(Y<>group) = 1/(1+Exp(-Nice Model)) was then determined. Sensitivity, specificity, positive 
predictive value, negative predictive value and likelihood ratio were determined for each cutoff value 
of the NiceModel. 
Statistical analysis was then carried out on the validation patient cohort (n=154). The main parameters of 
both cohorts were compared using Chi2 test or Fischer’s exact tests for nominal data, and by two-sample 
t tests for continuous data. The final model obtained in the training patient cohort was applied to the 
validation patient cohort. The diagnostic performance of the model was determined by constructing a 
ROC curve and calculating the AUROC curve for prediction of patients with NAS ≥5. 
All statistical analyses were performed using NCSS 2007 software. 
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8 
Results 
Pathological findings and univariate analysis 
The distribution of NAS scores among the 310 patients in the training patient cohort is shown in the 
table 1. Using Kleiner’s classification, 39 patients had NAS ≥5. Fibrosis reported using bridging 
fibrosis grade was absent in 13 patients, mild perivenular and/or periportal fibrosis in 281, septal 
fibrosis in 15 patients and severe fibrosis in one patient.  
Using the univariate analysis (Table 2), patients with NAS ≥5 had higher waist circumference, ALT, 
γGT, triglyceride levels, blood glucose levels, C peptide, glycosylated hemoglobin, HOMA-IR, 
ferritin and CK18 fragment levels compared to patients with NAS <5. HDL-cholesterol was lower in 
the more severe patients. Rates of type 2 diabetes mellitus and MS were also higher in patients with 
NAS ≥5 (Table 2). Neither age nor body mass index (BMI) were associated with NAS ≥5.  
 
Multivariate analysis 
Multivariate analysis included a model combining ALT, γGT, HOMA-IR, CK18 fragment levels, 
gender and MS in the training patient cohort. ALT (OR=1.04 [95%CI: 1.01-1.07], p=0.002), MS 
(OR=7.3, [95%CI: 1.8-29.4], p=0.005) and CK18 fragments (OR=1.003, [95%CI: 1.0006-1.005], 
p=0.044) were the only independent variables when NAS ≥5 was the judgment criterion (Table 3). 
 
CK18 fragments, ALT and IDF metabolic syndrome for the prediction of NAS ≥5  
AUROC curves for CK18 fragments, ALT and MS were assessed for the prediction of liver disease 
(NAS ≥5) in the training patient cohort. The AUROC curves were 0.74, 0.78 and 0.74 for the CK18 
fragment levels, ALT and MS respectively for the prediction of NAS ≥5. 
 
Model to predict NAS ≥5 in morbidly obese patients 
A new model combining these three values was constructed by logistic regression in the training 
patient cohort, the “Nice Model”. The equation of this model was: -5.654 + 3.780E-02*ALT (IU/L) + 
2.215E-03*CK18 fragment levels (IU/L) + 1.825*(Presence of MS=1). The AUROC curve for the 
prediction of NAS ≥5 was 0.88 (Figure 1). The diagnostic accuracy of the logarithmic transformation 
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9 
of the Nice Model (Prob(Y<>group) = 1/(1+Exp(-Nice Model)) is shown in Table 4. The best cutoff 
value was 0.14. This value was associated with a sensitivity of 0.84, a specificity of 0.86, a positive 
predictive value of 0.44 and negative predictive value of 0.98. The prevalence of NAS ≥5 was 0.12.  
The distribution of values from the Nice Model according to liver histology in the training patient 
cohort is shown in Figure 2. Box plots were constructed either separating patients into simple steatosis 
(NAS≤2), borderline group (3≤NAS≤4) or definitive NASH (Figure 2A) or between NAS ≥5 and NAS 
<5 (Figure 2B).  Nice Model values were significantly higher in patients with NAS ≥5 compared to 
borderline (p<0.00001) and to simple steatosis groups (p<0.00001). Nice Model values in the 
borderline group were also significantly higher than in the simple steatosis group (p<0.00001). In the 
same way, patients with NAS ≥5 had significantly higher Nice Model values compared to patients with 
NAS <5 (P<0.0001).  
 
Evaluation of the Nice Model in the validation cohort of morbidly obese patients 
The training patient and validation patient cohort were similar in terms of age, gender, BMI, ALT, 
CK18 fragment levels, prevalence of MS, as shown in Table 5. The number of patients with NAS ≥5 
was also similar in the two cohorts (12.6% versus 9%, P=NS). AUROC curves for the prediction of 
NAS≥5 was 0.83 (Figure 1).  
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10 
Discussion 
We propose a new composite scoring system (Nice Model) based on ALT, CK18 fragment levels and 
the presence of MS to diagnose NAS ≥5 in morbidly obese patients.  Indeed, the ALT, CK18 fragment 
levels or presence of MS separately were moderately predictive of NAS ≥5. The association of these 
three items in the Nice Model displayed an AUROC for NAS ≥5 of 0.88 and 0.83 in the training 
(n=310) and in the validation (n=154) cohort of morbidly obese patients respectively.  
Assessment of CK18 fragment levels has recently been proposed as a marker for NASH in patients 
exposed to NAFLD. The value of this marker was suggested by a pilot study and was confirmed in a 
large multicentre study in obese patients.20, 27 The disadvantage of the assessment of CK18 fragment 
levels is that it is not performed routinely in daily practice, but it has the advantage that it is a 
commercial ELISA kit. The CK18 fragment levels have also been studied in morbidly obese patients. 
In a cohort of 99 morbidly obese patients, CK18 fragment levels were found to be associated with 
NASH. CK18 fragment levels AUROC curve was 0.88.21 This value was higher than the one found in 
our training patient group (AUROC curve value only of 0.74) to predict NAS ≥5. Difference in the 
diagnostic accuracy could be due to the influence of fibrosis on the CK18 fragments levels. As 
reported by the previous authors CK18 fragments levels were significantly higher in subjects with 
moderate to severe fibrosis versus those with no or mild fibrosis.21  
In order to improve the prediction of definitive NASH, we attempted to develop a new scoring system 
combining variables significantly associated with NAS ≥5 in univariate and multivariate analysis. 
These variables were CK18 fragment levels, ALT and the presence of metabolic syndrome. ALT level 
has previously been related to inflammatory liver damage during NASH in morbidly obese patients 
and to an elevated risk of appearance of MS, diabetes and cardiovascular events.17, 28 However, ALT 
alone would not be sufficient for predicting NASH because it has been reported normal levels of 
transaminases in patients with proven steatohepatitis and/or significant or severe fibrosis due to 
NASH.29-31  
Presence of Metabolic syndrome in our model is not surprising because it is strongly associated with 
liver complications. However, in our cohort, metabolic syndrome alone is poorly predictive of 
definitive NASH.  
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11 
Our scoring system offers the original association of CK18 fragment levels, ALT and MS to diagnose 
definitive NASH. Several non-invasive tests have been proposed for the diagnosis of NASH. Among 
the different models proposed, 16, 19, 22, 33, 34  we evaluated only those with items available in our 
cohort.15, 17, 18 Respective AUROC of these models applied in the entire cohort (n=464) are 
summarized in table 6.  
One of the weaknesses of this study is that our model is developed among morbidly obese patients. 
The clinical utility of this model will be fully acquired only when a validation on overweight and 
simple obese patients will have been carried out. Another point is the relatively small number of 
patients with NAS≥5 which could limit the statistical power of analyses.  
Pure steatosis had classically a relatively good prognosis whereas steatohepatitis was associated with 
liver fibrosis. However, it was recently suggested that patients with low NAS could develop NASH 
and fibrosis progression.32 Even if patients with definitive NASH could have a more severe prognosis, 
clinicians should keep in mind that all patients with NAFLD should undergo periodic assessment and 
treatment.  
In conclusion, a new composite model, the Nice Model, for the diagnosis of definitive NASH in 
morbidly obese patients based on ALT and CK18 fragment levels and on the presence of a MS is 
proposed. The diagnostic accuracy of this model was better than using CK18 fragment levels, ALT 
and the presence of a MS alone. Possibility of the Nice Model to be an alternative to liver biopsy in the 
follow up of obese patients and in the evaluation of treatments aimed at preventing the progression of 
liver disease in these high risks patients should be assessed. The identification of non invasive scoring 
system independent of the severity of obesity and the ethnicity constitute an important challenge for 
the diagnosis of NASH. 
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Abbreviations: 
ALT: alanine aminotransferase 
AST: aspartate aminotransferase  
AUROC: area under receiver-operating characteristic (curve) 
BMI: body mass index  
BP: blood pressure 
CRP: C-reactive protein 
γGT: γ glutamyl transferase  
HDL: high-density lipoprotein  
HOMA-IR: homeostasis model assessment of insulin resistance 
LDL: low-density lipoprotein 
MS: metabolic syndrome 
NAFLD: non-alcoholic fatty liver disease 
NAS: NAFLD activity score  
NASH: non-alcoholic steatohepatitis  
ROC: receiver-operating characteristic  
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3 
TABLES  
Table 1: Distribution of parameters according to NAS score in the training morbidly obese 
patient cohort (n=310).  
NAS n Age (years) 
Gender 
(M/F) 
BMI 
(kg/m²) 
CK18 fragment 
levels (IU/L)  ALT (IU/L) 
IDF MS 
(Absent/Present) 
0 20 30.5 ± 9.2 0/20 43.7 ± 2.6 216.3 ± 114.6 21.0 ± 8.5 16/4 
1 105 40.2 ± 11.0 8/97 44.7 ± 4.7 231.3 ± 114.6 23.7 ± 10.9 59/46 
2 72 40.5 ± 10.0 10/62 44.4 ± 5.4 225.4 ± 138.3 31.8 ± 25.5 35/37 
3 59 40.8 ± 11.0 11/48 44.6 ± 4.8 253.4 ± 158.9 43.3 ± 21.1 25/34 
4 15 42.4 ± 8.7 5/10 45.5 ± 5.0 254.2 ± 130.6 38.6 ± 20.6 7/8 
5 36 41.0 ±10.3 9/27 45.3 ± 6.4 393.5 ± 250.4 63.0 ± 47.8 7/29 
6 3 50.6 ± 4.7 0/3 41.9 ± 2.3 935.2 ± 198.2 118.7 ± 28.3 0/3 
7 0 - - - - - - 
8 0 - - - - - - 
Results are expressed as means ± standard deviation, or as absolute numbers. Metabolic syndrome (MS) was 
defined according to the definition of the International Diabetes Federation (IDF). NAS: Non-Alcoholic Fatty 
Liver Disease Activity Score ; M: Male ; F: Female ; BMI: Body Mass Index; ALT: alanine amino-transferase. 
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4 
Table 2: Univariate analysis of the training patient cohort (n=310) according to the severity of 
liver disease.  
 
 Liver disease according to NAFLD Activity Score (NAS) 
 NAS <5 (n=271) NAS ≥5 (n=39) P 
Age (years) 39.8 ± 10.8 41.7 ± 10.2 NS 
Gender (M/F) 34/237 9/30 NS 
BMI (kg/m²) 44.6 ± 4.8 45.0 ± 6.2 NS 
Waist circumference 
(cm) 119.7 ± 13.1 126.9 ± 15.6 0.002 
ALT (IU/L) 30.7 ± 20.1 67.4 ± 48.8 <0.0000001 
γGT (IU/L) 38.8 ± 34.2 73.6 ±54.4 <0.0000001 
HDL Cholesterol 
(mmol/L) 1.4 ± 0.3 1.3 ± 0.3 0.008 
Triglyceride (mmol/L) 1.65 ± 1.16 2.6 ± 2.1 0.00002 
Blood glucose level 
(mmol/L) 5.9 ± 2.2 7.6 ± 3.3 0.00006 
C-peptide (pmol/L) 1047.5 ± 405.2 1402.9 ± 442.8 0.000006 
Glycosylated 
hemoglobin (%) 5.9± 1.1  6.8 ± 1.6 0.000009 
HOMAIR 5.5 ± 5.9 9.2 ± 6.6 0.0007 
Ferritin (µmol/L) 74.3 ± 77.5 142.8 ± 165.6 0.00003 
CK18 fragment levels 
(IU/L) 234.9 ± 132.0 445.9 ± 292.5 <0.0000001 
Type 2 Diabetes (%) 19.6 43.6 0.03 
IDF MS (%) 47.6 82.1 0.003 
Patients were classified as without or with a NAFLD Activity Score (NAS) <5 or ≥5. Quantitative results are 
expressed as means ± standard deviation. Metabolic syndrome (MS) was defined according to the definition of the 
International Diabetes Federation (IDF); M :Male ; F :Female ; NS : Not Significant; BMI: Body Mass Index; ALT: 
alanine amino-transferase; γGT : Gamma Glutamyl Transpeptidase ; HDL: high density lipoprotein ; HOMA-IR: 
homeostasis model assessment of insulin resistance.  
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5 
Table 3: Multivariate analysis of the training patient cohort (n=310) according to the severity 
of liver disease.  
 
 Liver disease according to NAFLD Activity Score (NAS) 
 NAS ≥5 (n=39) versus NAS <5 (n=271) 
 P OR 95%CI 
ALT 0.002 1.04 1.01-1.07 
γGT 0.6 0.99 0.98-1.01 
HOMA-IR 0.6 0.98 0.92-1.05 
CK18 fragment 
levels  0.044 1.003 1.00006-1.005 
Gender 0.7 0.82 0.21-3.19 
IDF MS 0.005 7.3 1.8-29.4 
Patients were classified as without or with a NAFLD Activity Score (NAS) <5 or ≥5. Metabolic 
syndrome (MS) was defined according to the definition of the International Diabetes Federation (IDF); 
ALT: alanine amino-transferase; γGT: Gamma Glutamyl Transpeptidase; HOMA-IR: homeostasis model 
assessment of insulin resistance.  
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6 
Table 4: Diagnostic accuracy of the NiceModel to predict NAS ≥5 in the training cohort of 
morbidly obese patients (n=310). 
 
Cutoff value Sensitivity Specificity Likelihood 
ratio 
Positive 
Predictive 
value 
(prevalence 
0.12) 
Negative 
Predictive 
Value 
0.10 0.87 0.80 4.3 0.36 0.98 
0.12 0.87 0.81 4.6 0.38 0.98 
0.13 0.84 0.84 5.2 0.41 0.98 
0.14 0.84 0.86 5.9 0.44 0.98 
0.17 0.68 0.89 6.0 0.44 0.95 
0.20 0.58 0.92 6.9 0.47 0.94 
0.29 0.48 0.95 10.4 0.57 0.93 
0.51 0.35 0.97 14.0 0.65 0.92 
0.68 0.23 0.99 26.6 0.78 0.91 
0.83 0.16 0.99 38.1 0.9 0.91 
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7 
Table 5: Comparative analysis between the training (n=310) and the validation (n=154) cohort 
of morbidly obese patients. 
 
 
Training patient 
cohort (n=310) 
Validation patient 
cohort (n=154) P 
Age (years) 40.0±10.7 39.3±10.8 NS 
Gender (M/F) 43/267 19/135 NS 
BMI (kg/m²) 44.6±5.0 44.4±5.7 NS 
ALT (IU/L) 35.3±28.1 34.4±26.3 NS 
CK18 fragment levels 
(IU/L) 259.2±172.0 242.5±178.0 NS 
IDF MS 52% (161/310) 52% (80/154) NS 
Metabolic syndrome (MS) was defined according to the definition of the International Diabetes Federation (IDF); 
NS : Not Significant; M :Male ; F :Female ; BMI: Body Mass Index; ALT: alanine amino-transferase.  
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8 
Table 6: AUROC curves of published scoring systems applied in the entire cohort (n=464) to 
diagnose NAS≥5. 
   
Scoring system 
AUROC curve in the original 
study 
AUROC curve in the entire 
cohort (n=464) 
Dixon et al. (HAIR)17 0.9 0.77 
Gholam et al.18 0.82 0.79 
Palekar et al.15 0.76 0.44 
AUROC: area under receiver-operating characteristic. Among published scoring models only those with items 
available in the cohort were studied. 
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9 
Figure Legends 
 
Figure 1: NiceModel receiver-operating characteristic (ROC) curves for the diagnosis of 
definitive NASH (NAS ≥5) in morbidly obese patients.  
NiceModel ROC curves are shown for the training patient cohort (n=310) and validation 
patient cohort (n=154).   
 
 
Figure 2: Distribution of values for the NiceModel (based on ALT, CK18 fragment levels 
and the presence of IDF metabolic syndrome) according to the severity of liver histology 
in the training cohort (n=310).  
(A) Distribution according to NAS values: simple steatosis (NAS ≤2), borderline Group 
(3≤NAS≤4), and definitive NASH (NAS ≥5). (B) Distribution according to NAS values: NAS 
≥5 or NAS <5. 
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10 
STARD checklist for reporting of studies of diagnostic accuracy 
(version January 2003) 
 
 
Section and Topic Item 
# 
 On page # 
TITLE/ABSTRACT/ 
KEYWORDS 
1 Identify the article as a study of diagnostic 
accuracy (recommend MeSH heading 'sensitivity 
and specificity'). 
Page 1 
INTRODUCTION 2 State the research questions or study aims, such 
as estimating diagnostic accuracy or comparing 
accuracy between tests or across participant 
groups. 
Page 4 
METHODS    
Participants 3 The study population: The inclusion and 
exclusion criteria, setting and locations where 
data were collected. 
Page 5 
 4 Participant recruitment: Was recruitment based 
on presenting symptoms, results from previous 
tests, or the fact that the participants had 
received the index tests or the reference 
standard? 
Recruitment was based on 
systematic enrolment during 
bariatric surgery  
 5 Participant sampling: Was the study population a 
consecutive series of participants defined by the 
selection criteria in item 3 and 4? If not, specify 
how participants were further selected. 
All consecutive morbidly obese 
patients were analysed. The cohort 
was arbitrally split in a training and 
a validation cohort. 
 6 Data collection: Was data collection planned 
before the index test and reference standard 
were performed (prospective study) or after 
(retrospective study)? 
It is a prospective study. 
Test methods 7 The reference standard and its rationale. Systematic liver biopsy which is the 
Gold Standard for NASH 
 8 Technical specifications of material and methods 
involved including how and when measurements 
were taken, and/or cite references for index tests 
and reference standard. 
Yes, page 5 and 6 
 9 Definition of and rationale for the units, cut-offs 
and/or categories of the results of the index tests 
and the reference standard. 
“Definitive NASH” (NALFD Activity 
Score ≥5) was retained according 
to Kleiner’s classification. 
 10 The number, training and expertise of the 
persons executing and reading the index tests 
and the reference standard. 
All liver biopsies were read by a 
specialized pathologist (MCSP). 
Kleiner’s classification was secondly 
determined by MCSP and SP. 
 11 Whether or not the readers of the index tests and 
reference standard were blind (masked) to the 
results of the other test and describe any other 
clinical information available to the readers. 
Yes, the readers of the liver biopsy 
were blind to the results of the 
proposed model. 
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11 
Statistical methods 12 Methods for calculating or comparing measures 
of diagnostic accuracy, and the statistical 
methods used to quantify uncertainty (e.g. 95% 
confidence intervals). 
Comparisons were done using the 
Chi2 test or Fischer’s exact tests for 
nominal data and by two-sample t 
tests for continuous data. 
Multivariate analyses were 
performed using binary logistic 
regression with estimation of odds 
ratios (OR) and 95% confidence 
intervals (95%CI). Only variables 
with p<0.05 in multivariate analyses 
were retained for the final model. 
The diagnostic performance of this 
model was determined by 
constructing a receiver-operating 
characteristic (ROC) curve and 
calculating the area under ROC 
(AUROC) curve for predicting 
patients with NAS ≥5. 
 13 Methods for calculating test reproducibility, if 
done. 
Not done. 
RESULTS    
Participants 14 When study was performed, including beginning 
and end dates of recruitment. 
Page 5  
 15 Clinical and demographic characteristics of the 
study population (at least information on age, 
gender, spectrum of presenting symptoms). 
Table 1 and table 5  
 16 The number of participants satisfying the criteria 
for inclusion who did or did not undergo the 
index tests and/or the reference standard; 
describe why participants failed to undergo either 
test (a flow diagram is strongly recommended). 
All the patients satisfying the 
criteria for inclusion were enrolled in 
the study. 
Test results 17 Time-interval between the index tests and the 
reference standard, and any treatment 
administered in between. 
Clinical and biological data were 
collected few days before the 
bariatric sugery after overnight 
fasting. Liver biopsy was done 
during surgery. 
 
 18 Distribution of severity of disease (define criteria) 
in those with the target condition; other 
diagnoses in participants without the target 
condition. 
Among morbidly obese patients 
enrolled in the training cohort 
12.6% had a “definitive NASH” 
(NALFD Activity Score ≥5) 
 19 A cross tabulation of the results of the index tests 
(including indeterminate and missing results) by 
the results of the reference standard; for 
continuous results, the distribution of the test 
results by the results of the reference standard. 
The distribution of the test results 
by the results of liver biopsy is 
presented in Figure 2. 
 20 Any adverse events from performing the index 
tests or the reference standard. 
No adverse events occurred. 
Estimates 21 Estimates of diagnostic accuracy and measures of 
statistical uncertainty (e.g. 95% confidence 
intervals). 
AUROC curves of the scoring 
system were 0.88 and 0.83 in the 
training and in the validation group 
respectively. 
 22 How indeterminate results, missing data and 
outliers of the index tests were handled. 
A borderline group is determined in 
the Kleiner’s classification. 
Diagnostic accuracy is given in the 
table 4. 
 23 Estimates of variability of diagnostic accuracy 
between subgroups of participants, readers or 
centers, if done. 
AUROC curves of the scoring 
system were 0.88 and 0.83 in the 
training and in the validation group 
respectively. 
 24 Estimates of test reproducibility, if done.      Not done 
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12 
DISCUSSION 25 Discuss the clinical applicability of the study 
findings. 
ALT level and Metabolic syndrome 
determination are done routinely. 
Blood levels of apoptotic caspase-3 
generated CK18 fragment levels 
were measured using a commercial 
kit. External validation in non 
morbidly obese patients will be 
necessary. Pages 10 & 11. 
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Figure 1: NiceModel receiver-operating characteristic (ROC) curves for the diagnosis of definitive 
NASH (NAS ≥5) in morbidly obese patients.  
NiceModel ROC curves are shown for the training patient cohort (n=310) and validation patient 
cohort (n=154).   
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Figure 2: Distribution of values for the NiceModel (based on ALT, CK18 fragment levels and the 
presence of IDF metabolic syndrome) according to the severity of liver histology in the training 
cohort (n=310).  
(A) Distribution according to NAS values: simple steatosis (NAS ≤2), borderline Group (3≤NAS≤4), 
and definitive NASH (NAS ≥5). (B) Distribution according to NAS values: NAS ≥5 or NAS <5. 
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